Literature DB >> 15846369

Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation.

J Hendriks1, L Planelles, J de Jong-Odding, G Hardenberg, S T Pals, M Hahne, M Spaargaren, J P Medema.   

Abstract

APRIL, a proliferation-inducing ligand, is a member of the tumor necrosis factor (TNF) family that is expressed by various types of tumors and influences their growth in vitro and in vivo. Two receptors, transmembrane activator and cyclophilin ligand interactor (TACI) and B-cell maturation antigen (BCMA), bind APRIL, but neither is essential for the tumor-promoting effects, suggesting that a third receptor exists. Here, we report that APRIL specifically binds to heparan sulfate proteoglycans (HSPG) on the surface of tumor cells. This binding is mediated by the heparin sulfate side chains and can be inhibited by heparin. Importantly, BCMA and HSPG do not compete, but can bind APRIL simultaneously, suggesting that different regions in APRIL are critical for either interaction. In agreement, mutation of three lysines in a putative heparin sulfate-binding motif, which is not part of the TNF fold, destroys interaction with HSPG, while binding to BCMA is unaffected. Finally, whereas interaction of APRIL with HSPG does not influence APRIL-induced proliferation of T cells, it is crucial for its tumor growth-promoting activities. We therefore conclude that either HSPG serve as a receptor for APRIL or that HSPG binding allows APRIL to interact with a receptor that promotes tumor growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846369     DOI: 10.1038/sj.cdd.4401647

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  66 in total

1.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

2.  TNF superfamily member 13, APRIL, inhibits allergic lung inflammation.

Authors:  Yanping Xiao; Seiichi Motomura; Vadim Deyev; Eckhard R Podack
Journal:  Eur J Immunol       Date:  2010-12-01       Impact factor: 5.532

3.  Reduced APRIL expression induces cellular senescence via a HSPG-dependent pathway.

Authors:  Weifeng Ding; Shaoqing Ju; Shengyang Jiang; Li Zhu; Yueguo Wang; Huimin Wang
Journal:  Pathol Oncol Res       Date:  2009-05-26       Impact factor: 3.201

4.  Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Authors:  K Mahtouk; F W Cremer; T Rème; M Jourdan; M Baudard; J Moreaux; G Requirand; G Fiol; J De Vos; M Moos; P Quittet; H Goldschmidt; J-F Rossi; D Hose; B Klein
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

5.  APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway.

Authors:  Guihua Wang; Feng Wang; Weifeng Ding; Jingchun Wang; Rongrong Jing; Haiquan Li; Xudong Wang; Yueguo Wang; Shaoqing Ju; Huimin Wang
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

6.  Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.

Authors:  Alain Munafo; Anthony Priestley; Ivan Nestorov; Jennifer Visich; Mark Rogge
Journal:  Eur J Clin Pharmacol       Date:  2007-05-01       Impact factor: 2.953

7.  B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.

Authors:  Stacey R Dillon; Brandon Harder; Kenneth B Lewis; Margaret D Moore; Hong Liu; Thomas R Bukowski; Nels B Hamacher; Megan M Lantry; Mark Maurer; Cecile M Krejsa; Jeff L Ellsworth; Susan Pederson; Keith B Elkon; Mark H Wener; Maria Dall'Era; Jane A Gross
Journal:  Arthritis Res Ther       Date:  2010-03-19       Impact factor: 5.156

8.  Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID).

Authors:  Lilit Garibyan; Adrian A Lobito; Richard M Siegel; Matthew E Call; Kai W Wucherpfennig; Raif S Geha
Journal:  J Clin Invest       Date:  2007-05-10       Impact factor: 14.808

9.  Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

Authors:  J-F Rossi; J Moreaux; D Hose; G Requirand; M Rose; V Rouillé; I Nestorov; G Mordenti; H Goldschmidt; A Ythier; B Klein
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

10.  Synovial tissues concentrate secreted APRIL.

Authors:  Cem Gabay; Veit Krenn; Carine Bosshard; Christian Alexander Seemayer; Carlo Chizzolini; Bertrand Huard
Journal:  Arthritis Res Ther       Date:  2009-09-29       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.